These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 8153671)

  • 21. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials.
    Henry DH; Beall GN; Benson CA; Carey J; Cone LA; Eron LJ; Fiala M; Fischl MA; Gabin SJ; Gottlieb MS
    Ann Intern Med; 1992 Nov; 117(9):739-48. PubMed ID: 1416576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erythropoietin and renal anemia.
    Hörl WH
    Biotechnol Ther; 1991; 2(3-4):213-30. PubMed ID: 1845127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant human erythropoietin in anemia of prematurity.
    Whitehall JS; Patole SK; Campbell P
    Indian Pediatr; 1999 Jan; 36(1):17-27. PubMed ID: 10709119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human immunodeficiency virus infection, anemia, and survival.
    Moore RD
    Clin Infect Dis; 1999 Jul; 29(1):44-9. PubMed ID: 10433563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy.
    Shasha D; George MJ; Harrison LB
    Cancer; 2003 Sep; 98(5):1072-9. PubMed ID: 12942577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erythropoietin reduces anemia and transfusions after chemotherapy with paclitaxel and carboplatin.
    Dunphy FR; Dunleavy TL; Harrison BR; Boyd JH; Varvares MA; Dunphy CH; Rodriguez JJ; McDonough EM; Minster JR; McGrady MD
    Cancer; 1997 Apr; 79(8):1623-8. PubMed ID: 9118049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Downstaging Rai stage III B-chronic lymphocytic leukemia patients with the administration of recombinant human erythropoietin.
    Pangalis GA; Siakantaris MP; Angelopoulou MK; Vassilakopoulos TP; Dimopoulou MN; Kyrtsonis MC; Konstantopoulos K; Tsaftaridis P; Vaiopoulos GA; Kontopidou FN
    Haematologica; 2002 May; 87(5):500-6. PubMed ID: 12010663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer.
    Dusenbery KE; McGuire WA; Holt PJ; Carson LF; Fowler JM; Twiggs LB; Potish RA
    Int J Radiat Oncol Biol Phys; 1994 Jul; 29(5):1079-84. PubMed ID: 8083076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Tumor anemia. Overview of the role of human recombinant erythropoietin (r-hu-EPO) in treatment of tumor anemia].
    Monnerat C; Leyvraz S
    Praxis (Bern 1994); 1999 Jan; 88(5):178-88. PubMed ID: 10067375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of recombinant human erythropoietin versus transfusions in the treatment of zidovudine-related anemia in HIV-infected children.
    Allen UD; Kirby MA; Goeree R
    Pediatr AIDS HIV Infect; 1997 Feb; 8(1):4-11. PubMed ID: 11361510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The blue cross blue shield assessment technology review: summary of findings.
    Bennett CL
    Best Pract Res Clin Haematol; 2005; 18(3):423-31. PubMed ID: 15792916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance to recombinant human erythropoietin therapy: a real clinical entity?
    Stivelman JC
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):8-11. PubMed ID: 2669085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erythropoietin therapy in cancer patients.
    Doweiko JP; Goldberg MA
    Oncology (Williston Park); 1991 Aug; 5(8):31-7; discussion 38, 43-4. PubMed ID: 1834151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant human erythropoietin in cancer-related anemia: an evidence-based review.
    Desai J; Demetri GD
    Best Pract Res Clin Haematol; 2005; 18(3):389-406. PubMed ID: 15792913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical experience with epoetin alfa in the management of hemoglobin levels in orthopedic surgery and cancer. Implications for use in gynecologic surgery.
    Stovall TG
    J Reprod Med; 2001 May; 46(5 Suppl):531-8. PubMed ID: 11396387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Erythropoietin in the treatment of anemias].
    Spicka I; Klener P; Lachmanová J; Háber J
    Vnitr Lek; 1996 Mar; 42(3):197-9. PubMed ID: 8686210
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of epoetin alfa on quality of life during cancer chemotherapy: a fresh look at an old problem.
    Glaspy J
    Semin Hematol; 1997 Jul; 34(3 Suppl 2):20-6. PubMed ID: 9253780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant human erythropoietin in the treatment of the anaemia of cancer.
    Abels RI
    Acta Haematol; 1992; 87 Suppl 1():4-11. PubMed ID: 1574966
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The application of recombinant erythropoietin in anemic patients with cancer.
    Spivak JL
    Semin Oncol; 1992 Jun; 19(3 Suppl 8):25-8. PubMed ID: 1615336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.